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Abstract
 Aims—To compare the value of serial electrocardiographic (ECG) changes by the 2 most 
widely used ECG classification systems--the Minnesota Code (MC) and Novacode (Nova) for the 
prediction of subsequent coronary heart disease (CHD) and total mortality.
 Methods and Result—We studied 12-lead ECGs from 12,477 participants (average age 54 
years at baseline; 58% women; 76% non-Hispanic white) in the Atherosclerosis Risk in 
Communities (ARIC) Study, who were free of CHD at baseline in 1987, had both good quality 
ECGs at baseline and at first study-scheduled follow up visit, and had ECG QRS duration < 
120ms. A total 2,119 participants died (17%), including 280 CHD deaths during an average of 17 
years follow-up. Cox regression models assessed outcome associated with significant serial ECG 
changes by MC and Nova separately. For CHD death the Hazard ratio was 6.8 (95% confidence 
interval 3.5-13.3) for incident Nova myocardial infarction (MI), and 5.7 (95% confidence interval 
2.7-11.9) for MC-MI in a multivariable model adjusted for clinical, demographic characteristics, 
and ECG left ventricular hypertrophy. The increased risk for total mortality doubled for both Nova 
and MC serial ECG MI. Major evolving ST-T wave abnormalities alone were associated with a 
≥132% increased risk for CHD death and a 50% increased risk for total mortality by either Nova 
or MC.
 Conclusion—ECG serial change by both MC and Nova are equally valuable predictors for 
future fatal cardiac events and total mortality and hence equally useful prognostic indicators in 
clinical trials and epidemiologic studies.
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Well-defined criteria for clinically significant evolution of electrocardiographic (ECG) 
abnormalities are frequently called for.(1–4) The Minnesota Code (MC) was originally 
developed to determine cardiac-related disease prevalence in population studies in the early 
1960s.(5) Later, criteria were developed to document incident events using objective side-by-
side ECG comparison rules.(6–7) The Novacode (Nova) is an extension of the MC,(8–9) 
which provides a comprehensive hierarchical set of criteria for both prevalent ECG 
abnormalities and clinically significant serial ECG changes. Both systems have been used in 
many epidemiologic studies and clinical trials. We have previously compared MC and Nova 
in terms of their ability to detect prevalent ECG abnormalities in men and women separately 
and how these ECG abnormalities are predictive of future cardiovascular disease (CVD) 
events.(10,11) In the present study, we compared the value of serial ECG changes as detected 
by MC and Nova to predict subsequent incident fatal cardiac events and total mortality.
 METHODS
 Study Population
The Atherosclerosis Risk In Communities (ARIC) Study, is a population-based, multicenter 
prospective study to investigate the natural history and etiology of atherosclerotic and CVD 
events from 4 U.S. communities in Maryland, Minnesota, Mississippi, and North Carolina 
(n=15,792 men and women aged 45–64 years at enrollment). Participants were interviewed 
at home, and invited to a baseline clinical examination (1987–1989). They attended three 
further clinical examinations at approximately 3-year intervals, and received a follow-up 
telephone call yearly. Details of study design, protocol, sampling procedures, and selection 
and exclusion criteria have been published.(12) After excluding the participants with 
prevalent coronary heart disease (CHD) (ECG evidence or a history of myocardial infarction 
[MI]), angina, coronary artery bypass surgery, coronary angioplasty, or congestive heart 
failure at baseline, we only focused on those participants who had both good quality ECGs 
at baseline and at first study-scheduled follow up visit (at year-4), and had ECG QRS 
duration <120ms. There remained 12,477 participants for the present study (Supplementary-
Figure.1).
 Outcome Ascertainment
Relevant outcomes were incident CHD deaths and all-cause mortality. Deaths and 
hospitalization events were ascertained using annual follow-up calls to the cohort members, 
review of vital records, and community surveillance of hospitalized and fatal events. A CHD 
death was defined as lacking a probable non-CHD cause, and occurring in the context of a 
recent MI, chest pain within 72 hours of death, or a history of CHD occurring from the first 
triennial follow-up visit to December 31, 2006 with an average17 year follow-up. Events 
were classified independently by a separate committee. Detailed definitions for the diagnosis 
of acute MI and death due to CHD have been published.(13,14)
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Identical electrocardiographs (MAC PC, Marquette Electronics, Inc., Milwaukee, 
Wisconsin) were used in all clinic sites, and resting, 10-second standard simultaneous 12-
lead ECGs were recorded in all participants using strictly standardized procedures. The chest 
electrodes were located in precise positions. All ECGs were processed in a central ECG 
laboratory (EPICORE Center, University of Alberta, Edmonton, Alberta, Canada, and later 
at EPICARE Center, Wake Forest University, Winston-Salem, North Carolina), where they 
were visually inspected for technical errors and inadequate quality. The ECGs first 
processed by the Dalhousie ECG program were repeated for the present study using the 
2001 version of the GE Marquette 12-SL program (Marquette 12SL ECG Physician Guide, 
available at www.ge-healthcare.com). ECGs were classified according to the Nova and MC 
using variables derived from the median complex of the Marquette measurement matrix.
 ECG Serial Classification Criteria for Incident MI/Ischemia
Serial change Nova classification of incident MI/ischemia is based on the change of a score 
in the appearance of the duration and/or voltage of the Q wave exceeding specified limits 
and on whether an ST segment and T wave abnormality have evolved significantly from the 
reference ECG.(7,9) Nova classifies incident MI/Ischemia as I-Nova-5 (I for ‘incident’) with 
8 hierarchies: Incident Nova-MI was identified by I-Nova-5.1 to I-Nova-5.4, and I-
Nova-5.5/5.6 was for isolated incident ECG ischemia by Nova (Table-1 and 
Supplementary-1).
MC for classification of incident MI/ischemia incorporates 4 MC codes: Code 1 for Q and 
QS patterns, Code 4 for ST segment depression, Code 5 for T wave negativity and Code 9–2 
for ST segment elevation. All serial changes were confirmed by side-by-side ECG 
comparison of Q and ST-T change between the first and subsequent examinations. Serial 
change MC categorizes evolving Q codes as Q1 to Q8, and for evolving ST-T codes as 
STE-1, ST-T1 to ST-T7.(5–7) Additionally, in order to achieve equivalency with the I-Nova-5 
code, 8 hierarchic levels from I-MC-C.1 to I-MC-C.7 were combined as illustrated in 
Table-1 and Supplementary-2. Incident MC-MI was identified either by Q1 to Q7, or I-MC-
C.1 to I-MC-C.4, and I-MC-C5/C.6 was for isolated incident ECG ischemia by MC.
One difference between the Nova and MC is that Q wave smaller than 100µV are ignored in 
the MC, whereas Nova scores Q waves that are at least 20ms in duration and 75µV in 
amplitude.
 Statistical Analysis Methods
Frequency distributions of all ECG and non-ECG variables were first inspected to rule out 
anomalies and outliers possibly due to measurement artifacts. Descriptive statistics were 
used to determine mean, standard deviations, and percentiles for continuous variables, and 
frequencies and percents for categorical variables. Cox's proportional hazards analysis was 
used to assess the effects of serial change ECG variables on the risk of CHD death and total 
mortality, and comparison of MC or Nova predictors. Univariate and multivariate models 
were used in the analysis. Multivariate mode adjusted for the key demographic and clinical 
characteristics which included education, smoking status, alcohol use, hypertension, diabetes 
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mellitus, history of cancer, body mass index, systolic blood pressure, white blood cell, HDL, 
LDL, baseline glucose, insulin, fibrinogen, uric acid, creatinine, geographic regions, and 
ECG left ventricular hypertrophy (ECG-LVH) by MC/Nova –all defined in previous 
reports.(7,12–14) Analyses were performed with SAS version 9.1.3 (SAS Institute, Cary, 
North Carolina).
 RESULTS
Among 12,477 participants with ECGs both at baseline and at first triennial visit, the mean 
age at baseline was 54 years, 58% women and 76% non-Hispanic white. Of these, 32% had 
hypertension, 10% diabetes, and 5% major ECG ST-T abnormalities by either Nova or MC 
(3.6% by Nova and 3.8% by MC). During an average 17 years post first follow-up visit: total 
mortality 17.0% (2,119) and CHD death 2.2% (280) (Table-2).
Table 2 shows 0.43% (54) had new incident ECG MI by Nova (I-Nova-5.1 to I-Nova-5.4) 
and 0.39% (49) by MC (I-MC-C.1 to I-MC-C.4) at first follow-up visit. Furthermore, 4.0% 
(499) had any new Q/ST-T change by Nova (i.e. codes I-Nova-5.1 through I-Nova-5.7), and 
8.2% (1,017) had new codable MC serial change (codes I-MC-C.1 through I-MC-C.7). The 
agreement coefficient by Kappa for new incident MI by Nova and by MC was 0.678, 
P=0.384, where the disagreement was related to codable Q wave and their scores.
 Prognosis of new ECG MI for CHD death and total mortality
New incident ECG MI categories were strong predictors for CHD death and all-cause 
mortality (Table 3–4). Incident ECG MI by MC/Nova criteria had at least a 5.6 times higher 
[Hazard ratio (HR) 6.81, 95% confidence interval (CI) 3.49-13.3 for Nova, and HR 5.66, 
95% CI 2.70-11.9 for MC] in the multivariate models adjusted for demographic, clinical 
variables and ECG-LVH. Incident ECG MI by MC/Nova criteria doubled the risk for total 
mortality in all models (Table 4).
 Isolated incident ECG ischemia independently predicting CHD death and total mortality
Compared with incident ECG MI, major evolution of ST-T change alone was also a strong 
predictor for CHD death and total mortality (Tables 3 and 4). There was a 2–4 times 
increased risk for CHD death (HR 2.32, 95% CI 1.31-4.08 for I-Nova-5.5/5.6; and HR 2.55, 
95% CI 1.69-3.84 for I-MC-C.5/C.6). There was about 50% increased risk for total mortality 
by I-MC-C.5/C.6 or I-Nova-5.5/5.6 in the multivariate model. In summary, any new Q/ST-T 
serial change has ≥168% increased risk for CHD death and ≥47% increase risk for total 
mortality by either Nova or MC serial classification compared with no new Q/ST-T change 
group.
There was an interaction between the diagnosis of a clinical MI by the diagnostic committee 
and the appearance of a serial ECG MI or major Q/ST-T evolution at the first follow-up visit. 
ECG evolving new MI or major Q/ST-T with diagnostic clinic CHD MI (Supplementary 
3-4) increased the risk of CHD death by 7.5 times (HR 8.57, 95% CI 5.04-14.6) and doubled 
risk for total mortality (HR 2.29, 95% CI 1.61-3.24) (Supplementary-5). Noteworthy, 
evolving ECG major Q/ST-T by MC or Nova was also predictive of CHD and total mortality 
regardless of having adjudicated clinical MI at the same period or not. Evolving major Q/ST-
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T change in the absence of adjudicated clinical MI at first follow-up visit increased by 119% 
the risk for CHD death and indicated a 54% increased risk for total mortality as great as that 
for a clinic adjudicated MI without major serial ECG change (a 35% increase in risk).
 DISCUSSION
Cardiovascular disease is a major cause of death and disability worldwide(15) with the ECG 
contributing independent diagnostic and prognostic information.(16–21) Serial change 
classification for incident MI/ischemia by MC or Nova has played an important role in 
numerous clinical trials and epidemiologic studies.(5–11,21) Coding by either Nova or MC 
has been well suited for incorporation in computer analysis programs as well as by visual 
review.
This is the first study to evaluate and compare the predictive power of serial change criteria 
by these 2 ECG classification systems. The relative strength of the 2 systems for prediction 
of the separate endpoints of CHD death and total mortality varied slightly.
Evolving Q wave or ST-T as evidence of an incident MI or ischemic event has been 
demonstrated previously in publications that have related ECG serial change to CHD death 
and total mortality. including the Multiple Risk Factor Intervention Trial (MRFIT)(6) and 
Framingham study.(21) New incident ECG MI (with a major evolving Q wave or evolving 
minor Q wave plus evolving ST-T change) had a 4 times higher related risk for coronary 
mortality in the MRFIT. The present study showed that new incident ECG MI increased by 5 
times the risk for CHD death compared with those without any evolving Q/ST-T, and 
doubled the risk for total mortality.
In the present study, 95% (523/552) of MC evolving ST categories were documented as ST-
T1, ST-T3, and ST-T7 (major T wave inversion to major T-wave inversion with 100% 
increase), and showed similar or higher risks than in MRFIT. The adjusted relative risks for 
CHD death in the present study were HRs of 4.13, 1.82 and 3.31, respectively; and HRs of 
2.29, 1.30 and 1.75 for total mortality. The combined code for all of isolated evolving ST-T 
categories had a HR 2.55 by MC, and 2.32 by Nova for CHD death. According this study, 
the Minnesota code serial changes include more patients without apparent loss of specificity.
 Study Strengths and Limitations
We focused only on electronic ECG data. Also, the serial change was between the baseline 
examination and the first follow up exam that did not occur until 3 years later, so that it did 
not test those changes that might have occurred and regressed in the first three years of the 
study. The strength of the study is the large community-based population, long term follow-
up, standardized ECG recording and adjudicated outcomes.
 CONCLUSIONS
ECG serial change criteria by both MC and Nova are equally valuable classification systems 
for detection of incident MI/ischemia in clinical trials and epidemiologic studies. Any 
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incident ECG MI or isolated major evolving ST-T changes by Nova or MC are independent 
predictors for fatal cardiac events and all-cause mortality.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
ECG Serial Change Criteria for Incident Myocardial Infarction and Ischemia by the Minnesota Code and the 
Novacode
Category Novacode Minnesota Code*
Evolving Q wave
Major Q wave evolution I-Nova-5.1 I-MC-C.1 Q1
Moderate Q wave evolution with evolving ST-T I-Nova-5.2 I-MC-C.2 Q2,Q3,Q4
Moderate Q wave evolution with nonevolving ST-T I-Nova-5.3 I-MC-C.3 N/A
Borderline Q wave evolution with evolving ST-T I-Nova-5.4 I-MC-C.4 Q5,Q6,Q7
Evolving ST-T change
Profound ST-T evolution without evolving Q waves I-Nova-5.5 I-MC-C.5 ST-T1,ST-T3,STE-1
Evolving ST-T with nonevolving Q waves I-Nova-5.6.1 I-MC-C.6 ST-T2,ST-T4
Isolated ST-T evolution I-Nova-5.6.2 I-MC-C.6 ST-T5,ST-T6,ST-T7
Borderline Q wave change
Borderline Q wave evolution with nonevolving ST-T I-Nova-5.7 I-MC-C.7 Q8
No significant Q or ST-T evolution
No significant Q wave or ST-T evolution I-Nova-5.0 I-MC-C.0 Q0
New Incident Myocardial Infarction/Ischemia





New isolated major ischemia I-Nova-5.5/5.6 I-MC-C.5/C.6 ST-T1 to ST-T7,STE-1








including evolving Q/ST code by the Minnesota code, and combined MC serial change code (I-MC-C.X). See Supplementary 1–2 and Reference# 
7&9.
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Table 2
Characteristics of study participants including the outcomes during average 17 years follow-up
Characteristics at baseline (N=12,477)
Age (year) 54±6 Current smoking 3321 (26.66%)
Body mass index (kg/m2) 28±5 Hypertension 4001 (32.20%)
Systolic blood pressure (mmHg) 120±18 Diabetes mellitus 1259 (10.17%)
Diastolic blood pressure (mmHg) 73±11 LVH by Nova or MC* 650 (5.21%)
Women 7248 (58.09%) CHD Death** 280 (2.24%)
African-American 3048 (24.43%) Total Mortality** 2119 (16.98%)
ECG ischemia by Nova# ECG ischemia by combined MC#
Nova-5.5 194 (1.55%) MC-C.5 133 (1.07%)
Nova-5.6 254 (2.04%) MC-C.6 343 (2.75%)
Nova-5.7 509 (4.08%) MC-C.7 644 (5.16%)
Nova-5.8 2043 (16.37%) MC-C.8 1188 (9.52%)
Nova-5.0 9477 (75.96%) MC-C.0 10169 (81.50%)
ECG serial change for MI/Ischemia by Nova/ MC at first scheduled follow-up visit##
ECG serial change by MC
Q1 44 (0.35%) STE-1 17 (0.14%)
Q2 1 (0.01%) ST-T1 81 (0.65%)
Q3 0 ST-T2 2 (0.02%)
Q4 0 ST-T3 247 (1.98%)
Q5 1 (0.01%) ST-T4 2 (0.02%)
Q6 3 (0.02%) ST-T5 5 (0.04%)
Q7 0 ST-T6 3 (0.02%)
Q8 416 (3.33%) ST-T7 195 (1.56%)
Q0 11460 (91.85%)
ECG serial change by Nova ECG serial change by combined MC
I-Nova-5.1 11 (0.09%) I-MC-C.1 44 (0.35%)
I-Nova-5.2 9 (0.07%) I-MC-C.2 1 (0.01%)
I-Nova-5.3 22 (0.18%) I-MC-C.3 N/A
I-Nova-5.4 12 (0.10%) I-MC-C.4 4 (0.03%)
I-Nova-5.5 48 (0.38%) I-MC-C.5 328 (2.63%)
I-Nova-5.6 169 (1.35%) I-MC-C.6 224 (1.80%)
I-Nova-5.7 228 (1.83%) I-MC-C.7 416 (3.33%)





See Table-1 for serial change criteria.
*
ECG-LVH (Left Ventricular Hypertrophy by Cornell voltage or MC 3.1);
**
Outcomes-CHD death and total mortality during first scheduled follow-up visit to average 17 years follow-up;
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Table 3
CHD Death by Serial Change for the Novacode and the Minnesota Code During first scheduled follow-up visit 








I-Nova-5.1 to 5.4 13/54 (24%) 11.8 (6.76–20.7)* 6.81 (3.49–13.3)*
I-Nova-5.5 to 5.6 17/217 (8%) 3.99 (2.44–6.52)* 2.32 (1.31–4.08)**
I-Nova-5.7 12/228 (5%) 2.68 (1.50–4.78)* 1.88 (0.96–3.69)





4.26 (3.07–5.92) 2.68 (1.83–3.91)
Combined MC Serial Change#
I-MC-C.1 to C.4 11/49 (22%)* 11.4 (6.23–21.0)* 5.66 (2.70–11.9)*
I-MC-C.5 to C.6 40/552 (7%)* 4.06 (2.89–5.70)* 2.55 (1.69–3.84)*
I-MC-C.7 24/416 (6%)* 3.16 (2.07–4.83)* 2.55 (1.61–4.03)*





4.08 (3.13–5.31) 2.75 (2.01–3.75)
Note:
#
see Table-1 for serial change criteria.
§
events rates--n (%), the event rate is the number of events (n) divided by the number (N) in that category of ECG MI, or each I-MC-C and I-
Nova-5 codes, where rate is n/N (%).
§§
Adjusted for key demographic and clinical variables of age, gender, race, education, smoking status, alcohol use, diabetes, hypertension, cancer, 
body mass index, systolic blood pressure, white blood cell count, baseline glucose, insulin, fibrinogen, HDL, LDL, uric acid, creatinine, geographic 
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Table 4
Total Mortality by Serial Change for Novacode and Minnesota Code During First Scheduled Follow-up Visit 








I-Nova-5.1 to 5.4 27/54 (50%) 3.03 (2.07–4.43)* 2.07 (1.31–3.27)**
I-Nova-5.5 to 5.6 83/217 (38%) 2.38 (1.91–2.96)* 1.47 (1.13–1.91)**
I-Nova-5.7 71/228 (31%) 1.94 (1.53–2.46)* 1.59 (1.23–2.05)*





2.25 (1.93–2.62)* 1.58 (1.33–1.88)*
Combined MC Serial Change#
I-MC-C.1 to C.4 24/49 (49%) 2.83 (1.89–4.24)* 2.16 (1.38–3.27)*
I-MC-C.5 to C.6 185/552 (34%) 2.13 (1.84–2.48)* 1.56 (1.31–1.87)*
I-MC-C.7 104/416 (25%) 1.56 (1.28–1.90)* 1.28 (1.04–1.58)**





1.93 (1.71–2.18)* 1.47 (1.29–1.69)*
Note:
#
see Table-1 for serial change criteria.
*and§ see Table-3.
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